These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 15904961)
1. Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia. Scheetz MH; Bolon MK; Scarsi KK; Fotis MA; Postelnick MJ J Infect; 2006 Feb; 52(2):105-10. PubMed ID: 15904961 [TBL] [Abstract][Full Text] [Related]
2. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. Paladino JA; Sunderlin JL; Forrest A; Schentag JJ J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598 [TBL] [Abstract][Full Text] [Related]
3. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome. Nguyen LH; Hsu DI; Ganapathy V; Shriner K; Wong-Beringer A J Antimicrob Chemother; 2008 Mar; 61(3):714-20. PubMed ID: 18222951 [TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. Hsu DI; Okamoto MP; Murthy R; Wong-Beringer A J Antimicrob Chemother; 2005 Apr; 55(4):535-41. PubMed ID: 15728150 [TBL] [Abstract][Full Text] [Related]
5. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study. Deal EN; Micek ST; Reichley RM; Ritchie DJ Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902 [TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Gasink LB; Fishman NO; Weiner MG; Nachamkin I; Bilker WB; Lautenbach E Am J Med; 2006 Jun; 119(6):526.e19-25. PubMed ID: 16750968 [TBL] [Abstract][Full Text] [Related]
7. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354 [TBL] [Abstract][Full Text] [Related]
8. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415 [TBL] [Abstract][Full Text] [Related]
9. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669 [TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Kang CI; Kim SH; Kim HB; Park SW; Choe YJ; Oh MD; Kim EC; Choe KW Clin Infect Dis; 2003 Sep; 37(6):745-51. PubMed ID: 12955633 [TBL] [Abstract][Full Text] [Related]
11. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia? Wu PF; Lin YT; Wang FD; Yang TC; Fung CP Infection; 2018 Jun; 46(3):365-373. PubMed ID: 29556979 [TBL] [Abstract][Full Text] [Related]
12. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693 [TBL] [Abstract][Full Text] [Related]
14. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532 [TBL] [Abstract][Full Text] [Related]
15. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City]. Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285 [TBL] [Abstract][Full Text] [Related]
16. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use]. Jónsdóttir K; Kristinsson KG Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726 [TBL] [Abstract][Full Text] [Related]
17. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa. Ray GT; Baxter R; DeLorenze GN Clin Infect Dis; 2005 Aug; 41(4):441-9. PubMed ID: 16028150 [TBL] [Abstract][Full Text] [Related]
18. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED. Lee CC; Lee CH; Hong MY Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263 [TBL] [Abstract][Full Text] [Related]
19. Favourable outcomes in episodes of Pseudomonas bacteraemia when associated with tunnelled cuffed catheters (TCCs) in chronic haemodialysis patients. Golestaneh L; Laut J; Rosenberg S; Zhang M; Mokrzycki MH Nephrol Dial Transplant; 2006 May; 21(5):1328-33. PubMed ID: 16421157 [TBL] [Abstract][Full Text] [Related]
20. A five-year review of Pseudomonas aeruginosa bacteremia in children hospitalized at a single center in southern China. Zhang Q; Smith JC; Zhu Q; Guo Z; MacDonald NE Int J Infect Dis; 2012 Aug; 16(8):e628-32. PubMed ID: 22709682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]